Fair enough nothing wrong with a little bit of a different view... only way they won't get FDA is if the results are poor as in much worse than the results from the Australian paediatric data to date.
If the results are in the mid 60% accuracy range or less then I would assume Resapp won't apply to the FDA. But I've mentioned all of this before RR as I'm not just smelling red roses... we would be talking about a delay of around 8 to 12 months if the results were not that great. BUT the company will have 1100 to 1500 new results to feed into our machine learning algorithms so that way when we go through the entire process again the ResAppDX software will not get it wrong again the following time... it will be a given either way, obviously it would be 10 times better if it happens now rather than in a year's time...
Cheers
Red bar
Game On, page-215
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #